Search research articles
Contact Us
Filters
Showing results (11-20 of 450) with videos related to
Page
of 45
Sort By:
European Heart Journal
|
July 5, 2023
Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction
Stephen J Greene, Gregg C Fonarow
European Journal of Heart Failure
|
June 14, 2024
Bio-adrenomedullin: A weak biomarker for a STRONG patient
Antoni Bayes-Genis, Stephen J Greene
Journal of the American College of Cardiology
|
February 12, 2021
Improving In-Hospital Diuretic Therapy for Heart Failure: The Need for High-Quality Evidence
G Michael Felker, Stephen J Greene
Journal of the American College of Cardiology
|
June 30, 2018
Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction: Marker or Mediator?
Robert J Mentz, Stephen J Greene
Journal of the American College of Cardiology
|
March 19, 2021
Quadruple Medical Therapy for Heart Failure: Medications Working Together to Provide the Best Care
Stephen J Greene, Muhammad Shahzeb Khan
Joint Commission Journal on Quality and Patient Safety
|
November 29, 2021
Breaking Clinical Inertia in Heart Failure Management
Vishal N Rao, Stephen J Greene
European Journal of Heart Failure
|
September 18, 2015
Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction?
Stephen J Greene, Gregg C Fonarow
European Journal of Heart Failure
|
October 31, 2017
Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'?
Stephen J Greene, Robert J Mentz
JACC. Basic to Translational Science
|
August 1, 2018
Innovation in Diuretic Therapy: The Missing Ingredient for Treating Worsening Heart Failure Outside the Hospital?
Stephen J Greene, G Michael Felker
JACC. Heart Failure
|
August 18, 2020
The Maximally Tolerated Dose: The Key Context for Interpreting Subtarget Medication Dosing for Heart Failure
Stephen J Greene, Adam D DeVore
Page
of 45
Search research articles
Search
Showing results (11-20 of 450) with videos related to
Sort By:
Page
of 45
European Heart Journal
|
July 5, 2023
Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction
Stephen J Greene, Gregg C Fonarow
European Journal of Heart Failure
|
June 14, 2024
Bio-adrenomedullin: A weak biomarker for a STRONG patient
Antoni Bayes-Genis, Stephen J Greene
Journal of the American College of Cardiology
|
February 12, 2021
Improving In-Hospital Diuretic Therapy for Heart Failure: The Need for High-Quality Evidence
G Michael Felker, Stephen J Greene
Journal of the American College of Cardiology
|
June 30, 2018
Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction: Marker or Mediator?
Robert J Mentz, Stephen J Greene
Journal of the American College of Cardiology
|
March 19, 2021
Quadruple Medical Therapy for Heart Failure: Medications Working Together to Provide the Best Care
Stephen J Greene, Muhammad Shahzeb Khan
Joint Commission Journal on Quality and Patient Safety
|
November 29, 2021
Breaking Clinical Inertia in Heart Failure Management
Vishal N Rao, Stephen J Greene
European Journal of Heart Failure
|
September 18, 2015
Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction?
Stephen J Greene, Gregg C Fonarow
European Journal of Heart Failure
|
October 31, 2017
Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'?
Stephen J Greene, Robert J Mentz
JACC. Basic to Translational Science
|
August 1, 2018
Innovation in Diuretic Therapy: The Missing Ingredient for Treating Worsening Heart Failure Outside the Hospital?
Stephen J Greene, G Michael Felker
JACC. Heart Failure
|
August 18, 2020
The Maximally Tolerated Dose: The Key Context for Interpreting Subtarget Medication Dosing for Heart Failure
Stephen J Greene, Adam D DeVore
Page
of 45